169 related articles for article (PubMed ID: 9389558)
21. Cytokine-mediated modulation of HLA-class II, ICAM-1, LFA-3 and tumor-associated antigen profile of melanoma cells. Comparison with anti-proliferative activity by rIL1-beta, rTNF-alpha, rIFN-gamma, rIL4 and their combinations.
Mortarini R; Belli F; Parmiani G; Anichini A
Int J Cancer; 1990 Feb; 45(2):334-41. PubMed ID: 1689276
[TBL] [Abstract][Full Text] [Related]
22. Interleukin-10 is a growth factor for human melanoma cells and down-regulates HLA class-I, HLA class-II and ICAM-1 molecules.
Yue FY; Dummer R; Geertsen R; Hofbauer G; Laine E; Manolio S; Burg G
Int J Cancer; 1997 May; 71(4):630-7. PubMed ID: 9178819
[TBL] [Abstract][Full Text] [Related]
23. Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells.
Yang S; Darrow TL; Seigler HF
Cancer Res; 1997 Apr; 57(8):1561-8. PubMed ID: 9108460
[TBL] [Abstract][Full Text] [Related]
24. Human antigen-presenting cell/tumour cell hybrids stimulate strong allogeneic responses and present tumour-associated antigens to cytotoxic T cells in vitro.
Dunnion DJ; Cywinski AL; Tucker VC; Murray AK; Rickinson AB; Coulie P; Browning MJ
Immunology; 1999 Dec; 98(4):541-50. PubMed ID: 10594686
[TBL] [Abstract][Full Text] [Related]
25. CD4(+), HLA class I-restricted, cytolytic T-lymphocyte clone against primary malignant melanoma cells.
Somasundaram R; Robbins P; Moonka D; Loh E; Marincola F; Patel A; Guerry D; Herlyn D
Int J Cancer; 2000 Jan; 85(2):253-9. PubMed ID: 10629086
[TBL] [Abstract][Full Text] [Related]
26. CD4(+) T cells kill HLA-class-II-antigen-positive melanoma cells presenting peptide in vitro.
Brady MS; Lee F; Petrie H; Eckels DD; Lee JS
Cancer Immunol Immunother; 2000 Feb; 48(11):621-6. PubMed ID: 10663609
[TBL] [Abstract][Full Text] [Related]
27. Antigen presentation by interferon-gamma-treated endothelial cells and fibroblasts: differential ability to function as antigen-presenting cells despite comparable Ia expression.
Geppert TD; Lipsky PE
J Immunol; 1985 Dec; 135(6):3750-62. PubMed ID: 3934267
[TBL] [Abstract][Full Text] [Related]
28. Ex vivo enrichment of circulating anti-tumor T cells from both cutaneous and ocular melanoma patients: clinical implications for adoptive cell transfer therapy.
Mazzarella T; Cambiaghi V; Rizzo N; Pilla L; Parolini D; Orsenigo E; Colucci A; Modorati G; Doglioni C; Parmiani G; Maccalli C
Cancer Immunol Immunother; 2012 Aug; 61(8):1169-82. PubMed ID: 22207316
[TBL] [Abstract][Full Text] [Related]
29. Immune selection in murine tumors. Ph.d thesis.
Svane IM; Engel AM
APMIS Suppl; 2003; (106):1-46. PubMed ID: 12739251
[TBL] [Abstract][Full Text] [Related]
30. Surface antigenic profile of uveal melanoma lesions analysed with a panel of monoclonal antibodies directed against cutaneous melanoma.
Carrel S; Schreyer M; Gross N; Zografos L
Anticancer Res; 1990; 10(1):81-9. PubMed ID: 1692197
[TBL] [Abstract][Full Text] [Related]
31. Distinct mechanisms of loss of IFN-gamma mediated HLA class I inducibility in two melanoma cell lines.
Rodríguez T; Méndez R; Del Campo A; Jiménez P; Aptsiauri N; Garrido F; Ruiz-Cabello F
BMC Cancer; 2007 Feb; 7():34. PubMed ID: 17319941
[TBL] [Abstract][Full Text] [Related]
32. Common expression of melanoma tumor-associated antigens recognized by human tumor infiltrating lymphocytes: analysis by human lymphocyte antigen restriction.
Hom SS; Topalian SL; Simonis T; Mancini M; Rosenberg SA
J Immunother (1991); 1991 Jun; 10(3):153-64. PubMed ID: 1868040
[TBL] [Abstract][Full Text] [Related]
33. Plasmacytoid dendritic cells prime IFN-gamma-secreting melanoma-specific CD8 lymphocytes and are found in primary melanoma lesions.
Salio M; Cella M; Vermi W; Facchetti F; Palmowski MJ; Smith CL; Shepherd D; Colonna M; Cerundolo V
Eur J Immunol; 2003 Apr; 33(4):1052-62. PubMed ID: 12672071
[TBL] [Abstract][Full Text] [Related]
34. A B7-1-transfected human melanoma line stimulates proliferation and cytotoxicity of autologous and allogeneic lymphocytes.
Sulé-Suso J; Arienti F; Melani C; Colombo MP; Parmiani G
Eur J Immunol; 1995 Oct; 25(10):2737-42. PubMed ID: 7589065
[TBL] [Abstract][Full Text] [Related]
35. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells.
Le Blanc K; Tammik C; Rosendahl K; Zetterberg E; Ringdén O
Exp Hematol; 2003 Oct; 31(10):890-6. PubMed ID: 14550804
[TBL] [Abstract][Full Text] [Related]
36. Development of immunogenic colorectal cancer cell lines for vaccination: expression of CD80 (B7.1) is not sufficient to restore impaired primary T cell activation in vitro.
Habicht A; Lindauer M; Galmbacher P; Rudy W; Gebert J; Schackert HK; Meuer SC; Moebius U
Eur J Cancer; 1995 Dec; 31A(13-14):2396-402. PubMed ID: 8652275
[TBL] [Abstract][Full Text] [Related]
37. Mechanisms of lymphocyte adhesion to human vascular endothelial cells in culture. T lymphocyte adhesion to endothelial cells through endothelial HLA-DR antigens induced by gamma interferon.
Masuyama J; Minato N; Kano S
J Clin Invest; 1986 May; 77(5):1596-605. PubMed ID: 3084562
[TBL] [Abstract][Full Text] [Related]
38. Melanoma-reactive human cytotoxic T lymphocytes derived from skin biopsies of delayed-type hypersensitivity reactions induced by injection of an autologous melanoma cell line.
Waanders GA; Rimoldi D; Liénard D; Carrel S; Lejeune F; Dietrich PY; Cerottini JC; Romero P
Clin Cancer Res; 1997 May; 3(5):685-96. PubMed ID: 9815737
[TBL] [Abstract][Full Text] [Related]
39. Autologous B lymphoblastoid cell lines and long-term cultured T cells as stimulators in the mixed lymphocyte reaction: analysis of the role of HLA class II antigens as stimulatory molecules.
Santoli D; Radka SF; Igarashi M; Kreider BL; Ferrone S
J Immunol; 1986 Jul; 137(2):400-7. PubMed ID: 2941479
[TBL] [Abstract][Full Text] [Related]
40. Tumor surveillance: expression of the transporter associated with antigen processing (TAP-1) in ex-vivo human tumor samples and its elevation by in vitro treatment with IFN-gamma and TNF-alpha.
Nagy N; Vánky F; Klein E
Immunol Lett; 1998 Dec; 64(2-3):153-60. PubMed ID: 9870667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
